Factors Modulating Fibrates Response: Therapeutic Implications and Alternative Strategies

Panadero, M. I.; González, M. C.; Herrera, E.; Bocos, C.
September 2009
Endocrine, Metabolic & Immune Disorders - Drug Targets;Sep2009, Vol. 9 Issue 3, p219
Academic Journal
Peroxisome proliferator-activated receptor alpha (PPAR??) regulates transcription of genes involved both in lipid and glucose metabolism as well as in inflammation. Fibrates are PPARα ligands used to normalize lipid and glucose parameters and exert antiinflammatory effects. In fact, fibrates have already been demonstrated to benefit metabolic syndrome, type 2 diabetes and cardiovascular diseases. This article reviews the mechanism of action and the functional roles of fibrates, emphasizing the factors modulating their capacity to activate PPARα and affecting their effectiveness. These factors may possibly explain the findings obtained in animal studies and clinical trials with fibrates which showed either untoward effects and/or inefficient hypolipidemic action of PPARα activation. We also discuss briefly the natural and synthetic agonists of PPARαwhich are currently being developed and supposedly display greater effectiveness and fewer adverse effects than fibrates.


Related Articles

  • Cardiometabolic interventions - focus on transcriptional regulators. Joshua T. Chai; Choudhury, Robin P. // European Journal of Cardiovascular Medicine;2013, Vol. 2 Issue 3, p212 

    Cardiovascular disease (CVD) remains the largest healthcare burden in the Western world; and the increasing prevalence of type II diabetes mellitus, at least partially driven by a trend in lifestyle changes associated with global economic development, is likely to fuel this CVD burden worldwide....

  • Factor analysis of metabolic syndrome using direct measurement of insulin resistance in Chinese with different degrees of glucose tolerance. Chung-Ze Wu; Jiunn-Diann Lin; Jer-Chuan Li; Fone-Ching Hsiao; Chang-Hsun Hsieh; Shi-Wen Kuo; Yi-Jen Hung; Chieh-Hua Lu; Chih-Tuseng He; Dee Pei // Indian Journal of Medical Research;Apr2008, Vol. 127 Issue 4, p336 

    Background & objectives: With the increasing prevalence of type 2 diabetes and cardiovascular disease in Taiwan, the understanding of metabolic syndrome (MetS) becomes more important. The purpose of this study was to investigate the clustering patterns of the risk variables of the MetS with...

  • Metabolic syndrome & Framingham Risk Score: Observations from a coronary angiographic study in Indian patients. Khanna, Roopali; Kapoor, Aditya; Kumar, Sudeep; Tewari, Satyendra; Garg, Naveen; Goel, Pravin K. // Indian Journal of Medical Research;Feb2013, Vol. 137 Issue 2, p295 

    Background & objectives: Metabolic syndrome (MS) is an important determinant of cardiovascular (CV) risk. Framingham Risk Scores (FRS) often underestimate the CV risk in Asians, younger patients and those with MS. Asians often develop coronary artery disease (CAD) at a younger age and also have...

  • Advancing drug therapy of the metabolic syndrome. Grundy, Scott M // Nature Reviews Drug Discovery;May2009, Vol. 8 Issue 5, p341 

    The metabolic syndrome — a group of factors that raise the risk of cardiovascular disease and type 2 diabetes — is increasingly common. How might the challenges of developing improved therapies to normalize these risk factors be approached?

  • Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle. Hayden, Melvin R.; Tyagi, Suresh C. // Nutrition & Metabolism;2004, Vol. 1, p10 

    Background: The topical role of uric acid and its relation to cardiovascular disease, renal disease, and hypertension is rapidly evolving. Its important role both historically and currently in the clinical clustering phenomenon of the metabolic syndrome (MS), type 2 diabetes mellitus (T2DM),...

  • Metabolic Syndrome and Cardiovascular Mortality in Older Type 2 Diabetic Patients: A Longitudinal Study. Monami, Matteo; Lamanna, Caterina; Balzi, Daniela; Bartalucci, Francesca; Melani, Cecilia; Masotti, Giulio; Marchionni, Niccolô; Mannucci, Edoardo // Journals of Gerontology Series A: Biological Sciences & Medical ;Jun2008, Vol. 63 Issue 6, p646 

    Background. Although age does not seem to modify the association of the metabolic syndrome (MS) with cardiovascular risk in middle-aged individuals, no comparison of risks associated with MS between old and middle-aged persons has been reported so far. Methods. An observational study was...

  • Nutritional risk and metabolic syndrome in Korean type 2 diabetes mellitus. Wha Young Kim; Jung Eun Kim; Young Joo Choi; Kap Bum Huh // Asia Pacific Journal of Clinical Nutrition;2008 Supplement 1, Vol. 17, p47 

    The prevalence of diabetes mellitus (DM) and the metabolic syndrome (MetS) are rapidly increasing in Asia including Korea. In 2005, the Third Korea National Health and Nutrition examination survey (KNHANES III) reported that the prevalence of DM and MetS in adults was estimated to be 8.7% and...

  • Early cardiovascular changes occurring in diet-induced, obese insulin-resistant rats. Huisamen, Barbara; Dietrich, Daneel; Bezuidenhout, Nicole; Lopes, John; Flepisi, Brian; Blackhurst, Dee; Lochner, Amanda // Molecular & Cellular Biochemistry;Sep2012, Vol. 368 Issue 1/2, p37 

    The metabolic syndrome is recognized as a cluster of disturbances associated with obesity, type 2 diabetes and hypertension. Over the past two decades, the number of people with the metabolic syndrome has increased at an alarming rate. This increase is associated with the global epidemic of both...

  • Links between Metabolic Syndrome and Cardiovascular Autonomic Dysfunction. Garruti, G.; Giampetruzzi, F.; Vita, M. G.; Pellegrini, F.; Lagioia, P.; Stefanelli, G.; Bellomo-Damato, A.; Giorgino, F. // Experimental Diabetes Research;2012, Special section p1 

    Background. Type 2 diabetes (T2D) might occur within metabolic syndrome (MbS). One of the complications of T2D is an impaired (imp) cardiovascular autonomic function (CAF). Aims. In subjects with T2D and age ≤ 55 years, the prevalence of impCAF and its relationship with BMI, waist, HbA1c...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics